FSNUF - Celltrion launches biosimilar of AbbVie's Humira in US

2023-07-05 12:57:34 ET

South Korea's Celltrion ( OTC:CONIF ) has launched a high-concentration, citrate-free formulated biosimilar of AbbVie's ( NYSE: ABBV ) Humira in the US.

The biosimilar, which is called Yuflyma, was approved by the FDA in May. Yuflyma's list price is $6,576.50 per month, Celltrion said.

Humira, also known as adalimumab, has been a best-seller for AbbVie for years. The drug, which is used to treat a wide variety of autoimmune disorders, has been facing increased competition from biosimilars, including those launched by Novartis's ( NVS ) Sandoz unit, Coherus ( CHRS ), Amgen ( AMGN ), Fresenius ( OTCPK:FSNUF ) ( OTCPK:FSNUY ), Boehringer Ingelheim and Organon ( OGN ).

Humira was the world's top-selling drug for ten years in a row, generating sales of $21B for AbbVie in 2021. Biosimilars of the product began to appear on the US market in January 2023.

More on Humira biosimilars:

• More AbbVie Humira biosimilars launched (updated)
• Organon launches biosimilar of AbbVie's Humira
• AbbVie’s global bestseller to face knockoffs starting this week
• AbbVie’s global bestseller to face knockoffs starting this week

For further details see: